Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

26.49 +0.61 (+2.36%)
Streaming Delayed Price Updated: 9:34 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zenas BioPharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
News headline image
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ZBIO DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.